project id: TCGA-BLCA; case submitter id: TCGA-ZF-AA56; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.88; concentration: 0.16; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.9; rna integrity number: 8.8; age at index: 79; days to birth: -28937; days to death: 259; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Dead; year of birth: 1931; year of death: 2010; age at diagnosis: 28937; ajcc clinical t: T2a; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic stage: Stage III; ajcc pathologic t: T4a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; icd 10 code: C67.4; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Posterior wall of bladder; synchronous malignancy: No; tissue or organ of origin: Posterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2010; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1344; initial weight: 230.0; sample id: 72f50bb3-c7a3-49b5-8262-185eb830e17e; sample submitter id: TCGA-ZF-AA56-01A; portion id: 6fccecfd-cc8c-49b1-9f4b-af6498adfa4f; portion submitter id: TCGA-ZF-AA56-01A-31; slide id: 8e33d817-e4ee-4cdd-bed9-1be0916acbaa; slide submitter id: TCGA-ZF-AA56-01A-03-TS3; percent lymphocyte infiltration: 7.0; percent monocyte infiltration: 0.0; percent necrosis: 3.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 97.0; percent tumor nuclei: 65.0; section location: TOP;